Marina V Shestakova

List of Publications by Year
in descending order

180	3,083	218381	182168
papers	citations	26 h-index	51 g-index

198	198	198	3137
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily. Diabetes Care, 2013, 36, 858-864.	4.3	214
2	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	0.5	195
3	The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study). Diabetes Mellitus, 2016, 19, 104-112.	0.5	155
4	Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1637-1645.	1.8	154
5	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovascular Diabetology, 2018, 17, 150.	2.7	149
6	Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition. Diabetes Mellitus, 2017, 20, 1-121.	0.5	142
7	Electrode materials used for electrochemical oxidation of organic compounds in wastewater. Reviews in Environmental Science and Biotechnology, 2017, 16, 223-238.	3.9	130
8	Removal of carbamazepine from MBR effluent by electrochemical oxidation (EO) using a Ti/Ta2O5-SnO2 electrode. Applied Catalysis B: Environmental, 2018, 221, 329-338.	10.8	104
9	Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus, 2018, 21, 144-159.	0.5	101
10	Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes Mellitus, 2021, 24, 204-221.	0.5	99
11	Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and Metabolism, 2018, 15, 53-70.	0.4	99
12	Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2. Journal of Translational Medicine, 2014, 12, 337.	1.8	73
13	Removal of dichloromethane from ground and wastewater: A review. Chemosphere, 2013, 93, 1258-1267.	4.2	68
14	Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Research and Clinical Practice, 2016, 115, 90-95.	1.1	67
15	National register of diabetes mellitus in Russian Federation.. Diabetes Mellitus, 2015, 18, 5-22.	0.5	60
16	Regulation of Adipose Tissue Stem Cells Angiogenic Potential by Tumor Necrosis Factorâ€Alpha. Journal of Cellular Biochemistry, 2016, 117, 180-196.	1.2	52
17	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. Journal of Diabetes and Its Complications, 2017, 31, 1188-1196.	1.2	46
18	Adiponectin and Adiponectin Receptor Gene Variants in Relation to Type 2 Diabetes and Insulin Resistance-Related Phenotypes. Review of Diabetic Studies, 2008, 5, 28-37.	0.5	43

#	Article	IF	Citations
19	Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies. Diabetes Mellitus, 2017, 20, 220-230.	0.5	43
20	Sonoelectrocatalytic decomposition of methylene blue using Ti/Ta2O5â€“SnO2 electrodes. Ultrasonics Sonochemistry, 2015, 23, 135-141.	3.8	38
21	Electrochemical Water Treatment Methods. , 2017, , 47-130.		37
22	Contraception in perimenopausal women with diabetes mellitus. Gynecological Endocrinology, 2006, 22, 198-206.	0.7	36
23	Novel Ti/Ta2O5-SnO2 electrodes for water electrolysis and electrocatalytic oxidation of organics. Electrochimica Acta, 2014, 120, 302-307.	2.6	36
24	Sonoelectrochemical degradation of formic acid using Ti/Ta 2 O 5 -SnO 2 electrodes. Journal of Molecular Liquids, 2016, 223, 388-394.	2.3	28
25	Contrast-induced nephropathy in patients with type 2 diabetes during coronary angiography: Risk-factors and prognostic value. Diabetes Research and Clinical Practice, 2009, 86, S63-S69.	1.1	27
26	The PPARÎ³ Pro12Ala variant is associated with insulin sensitivity in Russian normoglycaemic and type 2 diabetic subjects. Diabetes and Vascular Disease Research, 2010, 7, 56-62.	0.9	27
27	Diagnosing Impaired Glucose Tolerance Using Direct Infusion Mass Spectrometry of Blood Plasma. PLoS ONE, 2014, 9, e105343.	1.1	27
28	Role of endothelial dysfunction in the development of cardiorenal syndrome in patients with type 1 diabetes mellitus. Diabetes Research and Clinical Practice, 2005, 68, S65-S72.	1.1	26
29	Trends in the epidemiology of diabetic retinopathy in Russian Federation according to the Federal Diabetes Register (2013â€“2016). Diabetes Mellitus, 2018, 21, 230-240.	0.5	24
30	Eco-friendly bleaching of indigo dyed garment by advanced oxidation processes. Journal of Cleaner Production, 2017, 158, 134-142.	4.6	23
31	Confirmation of a susceptibility locus for diabetic nephropathy on chromosome 3q23â€“q24 by association study in Russian type 1 diabetic patients. Diabetes Research and Clinical Practice, 2004, 66, 79-86.	1.1	22
32	Photoelectrocatalytic activity of ZnO coated nano-porous silicon by atomic layer deposition. RSC Advances, 2016, 6, 25173-25178.	1.7	22
33	Trends in the epidemiology of diabetic foot and lower limb amputations in Russian Federation according to the Federal Diabetes Register (2013â€“2016). Diabetes Mellitus, 2018, 21, 170-177.	0.5	22
34	Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Diabetes Mellitus, 2019, 22, 1-121.	0.5	20
35	Economic evaluation of type 2 diabetes mellitus burden and its main cardiovascular complications in the Russian Federation. Diabetes Mellitus, 2016, 19, 518-527.	0.5	20
36	Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal Diabetes Register (2013â€“2016). Diabetes Mellitus, 2018, 21, 160-169.	0.5	20

#	Article	IF	Citations
37	Effectiveness of gliclazide MR 60Âmg in the management of type 2 diabetes: analyses from the EASYDia trial. Diabetology and Metabolic Syndrome, 2018, 10, 30.	1.2	19
38	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv, 2022, 94, 216-253.	0.2	19
39	Molecular mechanisms of latent inflammation in metabolic syndrome. Possible role of sirtuins and peroxisome proliferator-activated receptor type Î³. Biochemistry (Moscow), 2015, 80, 1217-1226.	0.7	18
40	Type 2 diabetes and metabolic syndrome: identification of the molecular mechanisms, key signaling pathways and transcription factors aimed to reveal new therapeutical targets. Diabetes Mellitus, 2018, 21, 364-375.	0.5	18
41	A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2018, 146, 240-250.	1.1	17
42	Optimization of Ti/Ta2O5â€“SnO2 electrodes and reaction parameters for electrocatalytic oxidation of methylene blue. Journal of Applied Electrochemistry, 2016, 46, 349-358.	1.5	16
43	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	0.5	16
44	Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: Results from the longitudinal global discover study. American Heart Journal, 2022, 243, 232-239.	1.2	14
45	LEADER-4. Journal of Hypertension, 2016, 34, 1140-1150.	0.3	13
46	Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists. Diabetes Mellitus, 2022, 25, 27-49.	0.5	13
47	Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovascular Diabetology, 2017, 16, 137.	2.7	12
48	Pre-diabetes as an interdisciplinary problem: definition, risks, approaches to the diagnostics and prevention of type 2 diabetes and cardiovascular complications. Russian Journal of Cardiology, 2019, , 83-91.	0.4	12
49	Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Research and Clinical Practice, 2016, 112, 50-56.	1.1	11
50	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 39-48.	2.2	11
51	The role of the tissue renin-angiotensin-aldosterone system in the development of metabolic syndrome, diabetes mellitus and itsvascular complications. Diabetes Mellitus, 2010, 13, 14-19.	0.5	11
52	Metabolic characteristics and therapeutic potential of brown and ?beige? adipose tissues. Diabetes Mellitus, 2014, 17, 5-15.	0.5	11
53	Improved glycaemic control with BIAsp 30 in insulin-naÃ¯ve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. Current Medical Research and Opinion, 2009, 25, 2643-2654.	0.9	10
54	Guidelines for the Diagnosis and Treatment of testosterone deficiency (hypogonadism) in male patients with diabetes mellitus. Obesity and Metabolism, 2017, 14, 83-92.	0.4	10

#	Article	IF	Citations
55	Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion. Russian Journal of Cardiology, 2019, , 44-51.	0.4	10
56	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). Eurasian Heart Journal, 2021, , 6-61.	0.2	9
57	Study design and baseline characteristics of patients in the PRESENT study. Diabetes Research and Clinical Practice, 2008, 81, S3-S9.	1.1	8
58	Association of FTO, KCNJ11, SLC30A8, and CDKN2B polymorphisms with type 2 diabetes mellitus. Molecular Biology, 2015, 49, 103-111.	0.4	8
59	Â«DIARISKÂ» â€" the first national prediabetes and diabetes mellitus type 2 risk calculator. Diabetes Mellitus, 2021, 23, 404-411.	0.5	8
60	Prevalence and progression of chronic kidney disease among patients with type <scp>2</scp> diabetes: Insights from the <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 1956-1960.	2.2	8
61	The role of Â«metabolic memoryÂ» mechanisms in the development and progression of vascular complications of diabetes mellitus. Diabetes Mellitus, 2017, 20, 126-134.	0.5	8
62	Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients. Diabetes Research and Clinical Practice, 2019, 158, 107928.	1.1	7
63	Epidemiology of acute diabetes complications (coma) according to the Federal Diabetes register of the Russian Federation (2013â€"2016). Diabetes Mellitus, 2018, 21, 444-454.	0.5	7
64	Epidemiology of cardiovascular diseases among patients with diabetes mellitus according to the federal diabetes register of the Russian Federation (2013â€"2016). Diabetes Mellitus, 2019, 22, 105-114.	0.5	7
65	The clinical and epidemiological characteristics of hypogonadism in men with type 2 diabetes mellitus. Diabetes Mellitus, 2019, 22, 536-541.	0.5	7
66	DECLARE-TIMI 58 trial in the context of EMPA-REG OUTCOME and CANVAS. Diabetes Mellitus, 2019, 22, 592-601.	0.5	7
67	Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus. Diabetes Mellitus, 2019, 22, 305-327.	0.5	6
68	Russian multicentre type 2 diabetes screening program in patients with cardiovascular disease. Diabetes Mellitus, 2016, 19, 24-29.	0.5	6
69	Hyperglycemia and possible mechanisms of Î²-cell damage in patients with COVID-19. Diabetes Mellitus, 2020, 23, 229-234.	0.5	6
70	Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results. Archives of Drug Information, 2009, 2, 23-33.	1.6	5
71	TCF7L2 rs12255372 and SLC30A8 rs13266634 confer susceptibility to type 2 diabetes in a Russian population. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2009, 3, 219-223.	1.8	5
72	Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. Diabetes Mellitus, 2020, 23, 349-356.	0.5	5

#	Article	IF	Citations
73	Insulin degludec is a new ultra-long-acting insulin analogue. Diabetes Mellitus, 2014, 17, 91-104.	0.5	5
74	Rational approach to patients treatment with type 2 diabetes and obesity: results of the All-Russian observational program Â«AURORAÂ». Obesity and Metabolism, 2018, 15, 48-58.	0.4	5
75	Sakharnyy diabet 2 tipa i kognitivnye narusheniya. Diabetes Mellitus, 2008, 11, 61-66.	0.5	5
76	Circulating precursors of endothelial cells in patients with CHD and disturbed carbohydrate metabolism. Diabetes Mellitus, 2010, 13, 13-20.	0.5	5
77	Pharmacogenetics of hypoglycemic agents. Diabetes Mellitus, 2015, 18, 28-34.	0.5	5
78	The KCNJ11 E23K and ABCC8 exon 31 variants contribute to susceptibility to type 2 diabetes, glucose intolerance and altered insulin secretion in a Russian population. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2008, 2, 185-191.	1.8	4
79	Replication of association between polymorphisms of the pancreatic ATP-sensitive potassium channel and susceptibility to type 2 diabetes in two Russian urban populations. Open Life Sciences, 2010, 5, 67-77.	0.6	4
80	The role of mineral and bone disorders in the development and progression of cardiac and renal pathology in patients with type 1 diabetes mellitus of long duration. Diabetes Research and Clinical Practice, 2016, 118, 29-37.	1.1	4
81	Multidisciplinary lifestyle management approach in patients with type 2 diabetes mellitus in real clinical practice. Results of application â€œLife is easyâ€•programme in Russia. Diabetes Mellitus, 2019, 22, 115-126.	0.5	4
82	The new views on the state of the gut microbiota in obesity and diabetes mellitus type 2. Diabetes Mellitus, 2019, 22, 253-262.	0.5	4
83	An economic value of the glycated hemoglobin test in diabetes mellitus type 2 diagnosis. Diabetes Mellitus, 2019, 22, 504-514.	0.5	4
84	Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL. Diabetes Mellitus, 2011, 14, 75-80.	0.5	4
85	Biosimilars: presumption of guilt. Diabetes Mellitus, 2011, 14, 91-99.	0.5	4
86	Type 2 Diabetes Mellitus Facilitates Shift of Adipose-Derived Stem Cells Ex Vivo Differentiation toward Osteogenesis among Patients with Obesity. Life, 2022, 12, 688.	1.1	4
87	Mass spectrometry analysis of blood plasma lipidome as the method of disease diagnostics, evalution of effectiveness and optimization of drug therapy. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2015, 9, 95-105.	0.2	3
88	High level of glycated hemoglobin (HbA_{1c}) in patients with COVID-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus. Diabetes Mellitus, 2021, 23, 504-513.	0.5	3
89	Time in range is a tool for assessing the quality of glycemic control in diabetes. Diabetes Mellitus, 2021, 24, 282-290.	0.5	3
90	The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus. Diabetes Mellitus, 2010, 13, 106-109.	0.5	3

#	Article	IF	Citations
91	Obesity - a risk factor of renal pathology in patients with type 2 diabetes mellitus. Diabetes Mellitus, 2010, 13, 45-49.	0.5	3
92	COVID-19 and kidneys. Diabetes Mellitus, 2020, 23, 235-241.	0.5	3
93	Kommentarii endokrinologa k Rekomendatsiyam po sakharnomu diabetu, prediabetu i serdechno-sosudistym zabolevaniyam ESC-EASD 2007. Diabetes Mellitus, 2008, 11, 97-99.	0.5	3
94	Pharmacoeconomic assessment of type 2 diabetes mellitus care on the base of Endocrinology Research Centre, Moscow. Diabetes Mellitus, 2012, 15, 101-109.	0.5	3
95	New prospects in the treatment of diabetes mellitus. Diabetes Mellitus, 2012, 15, 109-114.	0.5	3
96	Glucose-lowering therapies in patients with diabetes mellitus and chronic kidney disease. Diabetes Mellitus, 2013, 16, 97-102.	0.5	3
97	Podocyte injury in diabetes mellitus. Diabetes Mellitus, 2014, 17, 39-50.	0.5	3
98	Glucose-dependent insulinotropic polypeptide - a new link in the development of obesity. Obesity and Metabolism, 2015, 12, 16-19.	0.4	3
99	Association of polymorphism rs7903146 gene TCF7L2 with low concentrations of autoantibodies in latent autoimmune diabetes of adults (LADA). Diabetes Mellitus, 2016, 19, 199-203.	0.5	3
100	Is Absence of Carbohydrate Metabolism Disorders in Patients with Prolonged History of Obesity due to Low Insulin Resistance or Preserved Insulin Secretion?. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2018, 73, 344-353.	0.2	3
101	Clinical, pathomorphological and immunohistochemical evaluation of tissue repair in diabetic foot ulcers. Diabetes Mellitus, 2018, 21, 490-496.	0.5	3
102	The prevalence of hypogonadism in men with type 2 diabetes mellitus in clinical practice. Diabetes Mellitus, 2019, 22, 127-130.	0.5	3
103	Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. Russian Journal of Cardiology, 2020, 25, 3919.	0.4	3
104	The effect of bariatric surgery on purine metabolism and gout. Obesity and Metabolism, 2020, 17, 138-146.	0.4	3
105	Ultrasound-assisted electrochemical treatment of wastewaters containing organic pollutants by using novel Ti/Ta2O5â€“SnO2 electrodes. , 2020, , 79-161.		2
106	Identifying the unmet needs of individuals with Type 2 diabetes: an international web-based survey. Journal of Comparative Effectiveness Research, 2021, 10, 613-624.	0.6	2
107	The Effects of Glucagon-Like Peptide Type 1 (GLP-1) and its Analogues in Adipose Tissue: Is there a way to Thermogenesis?. Current Molecular Medicine, 2021, 21, 527-538.	0.6	2
108	Early functional and microcirculatory changes in patients with type 1 diabetes mellitus and no apparent diabetic retinopathy. Diabetes Mellitus, 2021, 24, 243-250.	0.5	2

#	Article	IF	Citations
109	Oral semaglutide: the innovation in type 2 diabetes management. Diabetes Mellitus, 2021, 24, 273-281.	0.5	2
110	Features of carbohydrate metabolism and incretin secretion in patients with Cushing disease and acromegaly. Diabetes Mellitus, 2017, 20, 249-256.	0.5	2
111	Expert council resolution on regional program of early T2D detection, prevention and treatment in Russian Federation. Diabetes Mellitus, 2017, 20, 233-237.	0.5	2
112	Genetic parameters of wound healing in patients with neuropatic diabetic foot ulcers. Diabetes Mellitus, 2017, 20, 344-349.	0.5	2
113	Sovremennoe ponyatie?khronicheskaya bolezn' pochek?: metody diagnostiki, klinicheskoe znachenie. Diabetes Mellitus, 2008, 11, 4-7.	0.5	2
114	Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program. Diabetes Mellitus, 2010, 13, 57-60.	0.5	2
115	Cardiorenal syndrome in patients with chronic kidney disease and diabetes mellitus. Diabetes Mellitus, 2013, 16, 90-96.	0.5	2
116	Intraperitoneal insulin infusion: on the way to the artificial pancreas. Diabetes Mellitus, 2015, 18, 32-45.	0.5	2
117	Guidelines for the diagnosis and treatment of testosterone deficiency (hypogonadism) in male patients with diabetes mellitus (Draft). Diabetes Mellitus, 2017, 20, 151-160.	0.5	2
118	Is it beneficial to the state to provide insulin-treated diabetic patients with public funds for self-monitoring blood glucose?. Diabetes Mellitus, 2017, 20, 108-118.	0.5	2
119	Free-living use of artificial pancreas for children with type 1 diabetes: systematic review. Diabetes Mellitus, 2018, 21, 206-216.	0.5	2
120	The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus. Diabetes Mellitus, 2020, 23, 242-249.	0.5	2
121	Ð¡hronic kidney disease complications in patients with type 1 diabetes mellitus after simultaneous pancreas-kidney transplantation â€“ potential role of oxidative stress and glycation end products. Diabetes Mellitus, 2019, 22, 405-416.	0.5	2
122	Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. Diabetes Mellitus, 2022, 24, 479-486.	0.5	2
123	Sulfur Containing Acyclovir Derivatives: Synthesis, Cytotoxic Activity, and Cell Phenotype Studies. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 1269-1271.	0.4	1
124	Predictors of postprandial blood glucose response to biphasic insulin analogue therapy. Primary Care Diabetes, 2013, 7, 63-67.	0.9	1
125	Prospects for the use of fecal microbiota transplantation in obese patients with Type 2 Diabetes Mellitus for weight loss and improvement of insulin sensitivity. Diabetes Mellitus, 2021, 23, 541-547.	0.5	1
126	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment. Diabetes Mellitus, 2021, 24, 193-197.	0.5	1

#	Article	IF	Citations
127	Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues. Diabetes Mellitus, 2014, 17, 108-119.	0.5	1
128	TGF-Î² and FRF-21: association with coronary artery disease in patients with type 2 diabetes and obesity. Obesity and Metabolism, 2017, 14, 38-42.	0.4	1
129	Insulin glargine 300 U/ml in type 2 diabetes mellitus patients: results of the EDITION program (review). Problemy Endokrinologii, 2017, 63, 257-268.	0.2	1
130	Comparative pharmacoeconomic evaluation of the treatment of type 2 diabetes mellitus with insulin degludec and insulin glargine in basal-bolus insulin therapy. Problemy Endokrinologii, 2017, 63, 307-319.	0.2	1
131	Liraglutide as additional treatment to insulin in patient with latent autoimmune diabetes in adults (LADA): a case report. Endocrine Abstracts, 0, , .	0.0	1
132	Factors of tubulointerstitial lesions in diabetic kidneys. Diabetes Mellitus, 2009, 12, 61-65.	0.5	1
133	Liraglutid - vozmozhnosti kompleksnogo terapevticheskogo podkhoda v terapii SD 2 tipa. Diabetes Mellitus, 2009, 12, 3-6.	0.5	1
134	The results of open observational trial DIAMOND. Diabetes Mellitus, 2011, 14, 96-102.	0.5	1
135	Simultaneous pancreas-kidney transplantation: Pro et Contra. Diabetes Mellitus, 2011, 14, 32-37.	0.5	1
136	An analysis of the association between a polymorphism rs5219 of KCNJ11 and GFR in CKD development in patients with type 2 diabetes in Russian population. Problemy Endokrinologii, 2016, 62, 11-12.	0.2	1
137	Experimental Polymer Coating Provides Hemocompatibility to Glucose Sensors in Bloodstream. Journal of Biomaterials and Tissue Engineering, 2017, 7, 770-778.	0.0	1
138	Evaluation of biocompatibility of an experimental membrane for glucose sensors: the results of a prospective experimental controlled preclinical study involving laboratory animals. Problemy Endokrinologii, 2017, 63, 219-226.	0.2	1
139	The significance of circulating progenitor cells with osteogenic activity in the of atherosclerosis development in patients with type 2 diabetes mellitus. Obesity and Metabolism, 2019, 16, 62-69.	0.4	1
140	Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes. Diabetes Mellitus, 2019, 22, 159-164.	0.5	1
141	Relationship between telomerase activity and parameters of carbohydrate metabolism and vascular wall. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 33-39.	0.4	1
142	The role of advanced glycation end products in patogenesis of diabetic nephropathy. Diabetes Mellitus, 2022, 24, 461-469.	0.5	1
143	Vaccination of patients with diabetes mellitus. Diabetes Mellitus, 2022, 25, 50-60.	0.5	1
144	Adrenal incidentaloma. Part 2. Modern concepts of computed tomography semiotics of adrenal gland incidentalomas: algorithm of differential diagnosis. Terapevticheskii Arkhiv, 2021, 93, 1381-1388.	0.2	1

#	Article	IF	Citations
145	Chronic kidney disease risk calculator: new possibilities for predicting pathology in patients with diabetes mellitus. Consilium Medicum, 2022, 24, 224-233.	0.1	1
146	Introduction to Lilly Award session. Diabetes Research and Clinical Practice, 2006, 74, S33.	1.1	0
147	On the centenary of the insulin discovery. Diabetes Mellitus, 2021, 24, 11-16.	0.5	0
148	Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity: Results from a 48â€week, multicenter, nonâ€randomized, parallelâ€group, openâ€label study. Obesity Science and Practice, 2021, 7, 368-378.	1.0	0
149	The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists. Diabetes Mellitus, 2021, 24, 175-184.	0.5	0
150	Possibilities of predicting preclinical forms of cardiovascular diseases in young patients with type 1 diabetes mellitus using cardiac magnetic resonance imaging. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2021, 36, 51-58.	0.1	0
151	Novye sredstva vvedeniya insulinakak sposob preodoleniya ?psikhologicheskoy insulinorezistentnosti? u bol'nykh sakharnym diabetom. Diabetes Mellitus, 2008, 11, 77-79.	0.5	0
152	Issledovanie ADVANCE: vliyanie Noliprela - fiksirovannoy kombinatsii ingibitora APF (Perindoprila) i diuretika (Indapamida) - na razvitie serdechno-sosudistykh oslozhneniy u patsientov s sakharnym diabetom 2 tipa. Diabetes Mellitus, 2008, 11, 81-84.	0.5	0
153	Efficiency of insulin analogs in young patients with type 1 diabetes mellitus debut during pubertal period. Diabetes Mellitus, 2009, 12, 49-52.	0.5	0
154	IMPROVE observational program: safety and effectiveness of biphasic insulin aspart 30 in routine clinical practice. Overview of starting characteristics of the Russian patient cohort. Diabetes Mellitus, 2009, 12, 93-97.	0.5	0
155	Friedreichs ataxia in a diabetic patient. Diabetes Mellitus, 2010, 13, 120-124.	0.5	0
156	New indications for exenatide therapy of type 2 diabetes mellitus. Diabetes Mellitus, 2010, 13, 98-104.	0.5	0
157	Is it possible to achieve a safe glycated hemoglobin level during intensive hypoglycemic therapy? (results of ADVANCE study). Diabetes Mellitus, 2011, 14, 110-115.	0.5	0
158	Glibenclamide therapy: pros and cons. Diabetes Mellitus, 2011, 14, 92-96.	0.5	0
159	InÑretin-based therapy in patients with type 2 diabetes and chronic kidney disease. Diabetes Mellitus, 2012, 15, 59-66.	0.5	0
160	Efficacy and safety of treatment with human insulin analogues in daily management of insulin naive patients with type 2 diabetes mellitus: results of multicenter 52-week observational study A1chive. Diabetes Mellitus, 2012, 15, 115-121.	0.5	0
161	Early insulin therapy Coordination Council. Diabetes Mellitus, 2012, 15, 128-131.	0.5	0
162	Post-transplantation diabetes mellitus: an overview. Diabetes Mellitus, 2015, 18, 20-31.	0.5	0

#	Article	IF	Citations
163	Telomere biology and vascular ageing in patients with T2DM. Endocrine Abstracts, 0, , .	0.0	0
164	Nonglycemic effects of incretins in patients with long history diabetes type 1 and chronic kidney disease. Endocrine Abstracts, 0, , .	0.0	0
165	Simultaneous pancreas-kidney transplantation effect on stabilisation/progression of diabetic complications in patients with type 1 diabetes. Endocrine Abstracts, 0, , .	0.0	0
166	Ð˜Ð·ÑƒÑ‡ÐµÐ½Ð¸Ðµ ÐºÐ¾Ð»Ð¸Ñ‡ÐµÑÑ‚Ð²Ð° Ñ†Ð¸Ñ€ÐºÑƒÐ»Ð¸Ñ€ÑƒÑŽÑ‰Ð¸Ñ… Ð¿Ñ€Ð¾Ð³Ð¸Ð±ÐµÐ½Ð¸Ñ‚Ð¾Ð²Ñ‹ Ð²Ð»Ð¸	0.2	0
167	Novel approaches of glucose-lowering therapy in type 2 diabetes and chronic kidney disease. Problemy Endokrinologii, 2015, 61, 36-43.	0.2	0
168	Novel biomarkers of chronic kidney disease in diabetes. Endocrine Abstracts, 0, , .	0.0	0
169	Carbohydrate metabolism in patients with Cushing disease: a glance at the incretin system. Problemy Endokrinologii, 2016, 62, 67-68.	0.2	0
170	Renal dysfunction markers in patients with diabetes mellitus type 1 after kidney or simultaneous kidney-pancreas transplantation. Problemy Endokrinologii, 2016, 62, 14-16.	0.2	0
171	On the 100th anniversary of academician Y.H. Turakulov. Diabetes Mellitus, 2016, 19, 350-352.	0.5	0
172	Comparative analysis of glycemic control effectiveness and microvascular complications in patients with type 1 diabetes mellitus, treated with genetically engineered human insulin or human insulin analogues: A 10-year retrospective observational study. Diabetes Mellitus, 2016, 19, 388-396.	0.5	0
173	Glucagon-like peptide-2 and glucagon in patients with acromegaly and Cushingâ€™s disease: secretion features and influence on glucose metabolism. Problemy Endokrinologii, 2017, 63, 299-306.	0.2	0
174	The psychological component of comprehensive lifestyle modification program in overweight (obese) patients with type 2 diabetes mellitus. Problemy Endokrinologii, 2018, 64, 93-104.	0.2	0
175	Genetic Variants Associated with the Development of Type 2 Diabetes: Approaches to Their Identification. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 44-53.	0.2	0
176	Simultaneous pancreasâ€kidney transplantation in type 1 diabetes mellitus. Clinical options. Diabetes Mellitus, 2020, 23, 275-282.	0.5	0
177	What are new opportunities for clinical practice the VERIFY study opens and which values for native diabetes patients? Joint conclusion on the advisory board results. November 6, 2019. Diabetes Mellitus, 2020, 23, 106-110.	0.5	0
178	Advanced glycation end products and oxidative stress as a basis for metabolic abnormalities in patients with type 1 diabetes after successful simultaneous pancreas-kidney transplantation. Terapevticheskii Arkhiv, 2021, 93, 1155-1163.	0.2	0
179	Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day. Terapevticheskii Arkhiv, 2021, 93, 1203-1208.	0.2	0
180	Relationship between telomerase activity and parameters of carbohydrate metabolism and vascular wall. Cardiovascular Therapy and Prevention (Russian Federation), 2019, 18, 33-39.	0.4	0